Davita (DVA) Downgraded by TheStreet

Share on StockTwits

Davita (NYSE:DVA) was downgraded by stock analysts at TheStreet from a “b-” rating to a “c+” rating in a report released on Thursday.

A number of other analysts also recently weighed in on DVA. Zacks Investment Research downgraded Davita from a “buy” rating to a “hold” rating in a report on Wednesday, August 1st. JPMorgan Chase & Co. upgraded Davita from an “underweight” rating to a “neutral” rating in a report on Thursday, September 13th. ValuEngine upgraded Davita from a “hold” rating to a “buy” rating in a report on Tuesday, October 9th. Raymond James downgraded Davita from a “strong-buy” rating to a “market perform” rating in a report on Thursday. Finally, Royal Bank of Canada increased their price objective on Davita from $70.00 to $78.00 and gave the company a “sector perform” rating in a report on Thursday. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $84.75.

NYSE DVA traded down $0.45 on Thursday, reaching $69.70. The company had a trading volume of 2,486,230 shares, compared to its average volume of 1,943,652. The company has a market capitalization of $12.70 billion, a price-to-earnings ratio of 20.99, a PEG ratio of 0.98 and a beta of 1.09. Davita has a fifty-two week low of $53.78 and a fifty-two week high of $80.71. The company has a quick ratio of 1.88, a current ratio of 1.90 and a debt-to-equity ratio of 1.82.

Davita (NYSE:DVA) last posted its quarterly earnings data on Wednesday, November 7th. The company reported $0.56 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.89 by ($0.33). The company had revenue of $2.85 billion during the quarter, compared to analyst estimates of $2.93 billion. Davita had a net margin of 5.39% and a return on equity of 13.37%. The business’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.81 earnings per share. Research analysts expect that Davita will post 4 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. California Public Employees Retirement System boosted its position in Davita by 8.6% during the second quarter. California Public Employees Retirement System now owns 571,830 shares of the company’s stock valued at $39,708,000 after acquiring an additional 45,102 shares during the last quarter. Hikari Tsushin Inc. boosted its position in Davita by 10.5% during the second quarter. Hikari Tsushin Inc. now owns 74,410 shares of the company’s stock valued at $5,624,000 after acquiring an additional 7,050 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Davita during the second quarter valued at $3,421,000. Tibra Equities Europe Ltd bought a new stake in Davita during the second quarter valued at $1,627,000. Finally, Janus Henderson Group PLC boosted its position in Davita by 3.0% during the second quarter. Janus Henderson Group PLC now owns 1,284,092 shares of the company’s stock valued at $89,168,000 after acquiring an additional 37,362 shares during the last quarter. 87.36% of the stock is currently owned by institutional investors and hedge funds.

About Davita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: What is Compound Annual Growth Rate (CAGR)?

Analyst Recommendations for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.